Lake Street Capital Issues Pessimistic Forecast for Sensus Healthcare (NASDAQ:SRTS) Stock Price

Sensus Healthcare (NASDAQ:SRTS) had its target price dropped by stock analysts at Lake Street Capital from $18.00 to $13.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s target price would suggest a potential upside of 183.84% from the stock’s previous close.

Several other analysts have also weighed in on SRTS. Maxim Group upped their target price on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a report on Friday, November 15th. HC Wainwright upped their price target on shares of Sensus Healthcare from $11.00 to $12.00 and gave the company a “buy” rating in a report on Monday, February 10th.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $4.58 on Tuesday. Sensus Healthcare has a fifty-two week low of $3.09 and a fifty-two week high of $9.33. The firm has a 50-day simple moving average of $6.13 and a 200-day simple moving average of $6.68. The company has a market capitalization of $75.55 million, a price-to-earnings ratio of 11.45 and a beta of 1.28.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. Equities research analysts forecast that Sensus Healthcare will post 0.32 EPS for the current year.

Hedge Funds Weigh In On Sensus Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SRTS. JPMorgan Chase & Co. purchased a new stake in Sensus Healthcare during the 4th quarter worth approximately $27,000. Truvestments Capital LLC acquired a new stake in shares of Sensus Healthcare during the third quarter worth approximately $32,000. Barclays PLC bought a new stake in shares of Sensus Healthcare in the fourth quarter worth $35,000. BNP Paribas Financial Markets acquired a new stake in Sensus Healthcare in the fourth quarter valued at $47,000. Finally, IFP Advisors Inc bought a new position in Sensus Healthcare during the 4th quarter valued at $95,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.